The German company BioNTech expects to seek approval from regulators for Covid jabs suited for younger children of five- to 11-year-olds.
The BioNTech Company, which was behind Pfizer vaccine, expected to file results of trial as early as mid-October.
“Already over the next few weeks we will file the results of our trial in five- to 11-year-olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” BioNTech’s chief medical officer, Özlem Türeci, said.
Türeci said her company was working on producing the vaccine. She pointed out that it was the same product being administered to adults and children aged 12 and older.
“Things are looking good, everything is going according to plan,” said the chief executive, Ugur Şahin, who added that the company was also expecting trial data for younger children aged over six months.
Covid cases rise in Germany
Top health officials in Germany urged citizens to get the Covid vaccination.
Also, they warned that if the numbers stay low, the hospitals in the country would be brimming with Covid cases.
“We need at least 5 million vaccinations for safe autumn and winter,” said the Health Minister, Jens Spahn, in a tweet.
Over 50.9 million people, or 61%, in Germany, have received their full vaccination.
However, the numbers are still less than in other countries in Europe.
While new COVID19 cases have been rising again, daily vaccination rates have been declining for weeks now.
The disease control agency in Germany reported on Saturday 10,835 new COVID19 cases, up from 10,303 the week before.